Next Article in Journal
Evaluation of the Association between the Risk of Central Retinal Artery Occlusion and the Concentration of Environmental Air Pollutants
Previous Article in Journal
Differential Efficacy of Neurofeedback in Children with ADHD Presentations
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
J. Clin. Med. 2019, 8(2), 207; https://doi.org/10.3390/jcm8020207

Chimeric Antigen Receptor T-Cells: The Future Is Now

1
Department of Medicine, Northside Hospital Cancer Institute, Atlanta, GA 30342, USA
2
Department of Medicine, University of Pittsburgh Center East, Monroeville, PA 15146, USA
3
Blood and Marrow Transplant, Acute Leukemia and Immunotherapy Program, Northside Hospital, Atlanta, GA 30342, USA
*
Author to whom correspondence should be addressed.
Received: 15 January 2019 / Revised: 29 January 2019 / Accepted: 31 January 2019 / Published: 7 February 2019
(This article belongs to the Special Issue Hematopoietic Cell Transplantation and Cellular Therapy: A New Era)
Full-Text   |   PDF [584 KB, uploaded 14 February 2019]   |  

Abstract

The immune system acting via cancer immune-surveillance is considered a potential target for improving outcomes among some malignancies. The ability to harness immune cells, engineer them and educate them to target cancer cells has changed the paradigm for treating non-Hodgkin’s lymphomas (NHL) and acute lymphoblastic leukemia (ALL). Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable anti-tumor activity against refractory B cell malignancies. Ongoing research aims to expand the scope of this adoptive cell therapy, understanding mechanisms of resistance and reducing toxicity. In this review, we will discuss the current scope of CAR T-cell therapy and ongoing future applications. View Full-Text
Keywords: Chimeric; cellular; immunotherapy; T cell Chimeric; cellular; immunotherapy; T cell
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Mchayleh, W.; Bedi, P.; Sehgal, R.; Solh, M. Chimeric Antigen Receptor T-Cells: The Future Is Now. J. Clin. Med. 2019, 8, 207.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top